Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7077229 | 0.93 | F2 (0.33) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL5611550 | 0.82 | TSHR (0.34) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL7074197 | 0.76 | RARB (0.38) | TSHRCYP3A4HCAR2 | |
| SCHEMBL1498029 | 0.74 | TSHR (0.44) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL1957697 | 0.72 | TSHR (0.37) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL9222485 | 0.71 | TSHR (0.46) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL5612429 | 0.70 | HCAR2 (0.40) | TSHRHCAR2KDM4E | |
| Bicarbonate SCHEMBL9083427 | 0.70 | ALDH1A1 (0.44) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| Bicarbonate SCHEMBL27364872 | 0.70 | ALDH1A1 (0.44) | TSHRABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL11757622 | 0.69 | HCAR2 (0.31) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140206557-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8575303-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257374-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | TSHR 2514/4885ABCB11 4824/4885CYP3A4 4860/4885 |
| US-20110256550-A1 | Novel reagents for directed biomarker signal amplification | RNGTT, CAPG, CD2BP2 | TSHR 2514/4885ABCB11 4824/4885CYP3A4 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.